The company is actively pursuing growth through acquisitions and new product launches. Its pharmaceutical services division has secured multiple contracts as clients shift production to the United States from Europe and Asia. Management has provided long-term revenue growth targets, projecting growth in the 3-6% range for 2026-2027 and 7% or more from 2028 onward. However, analysts note potential concerns regarding the company's significant debt load and negative impacts from currency exchange rate fluctuations.